Glenmark Pharmaceuticals Limited (NSE: GLENMARK)
India
· Delayed Price · Currency is INR | Market Cap | 413.80B |
| Revenue (ttm) | 130.80B |
| Net Income (ttm) | -8.75B |
| Shares Out | 282.19M |
| EPS (ttm) | -31.01 |
| PE Ratio | n/a |
| Forward PE | 26.07 |
| Dividend | 2.50 (0.17%) |
| Ex-Dividend Date | Sep 13, 2024 |
| Volume | 421,231 |
| Open | 1,492.65 |
| Previous Close | 1,492.65 |
| Day's Range | 1,458.55 - 1,494.20 |
| 52-Week Range | 761.00 - 1,830.95 |
| Beta | 0.87 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/n... [Read more]
Financial Performance
Financial StatementsNews
HSBC cuts target price for Glenmark Pharma shares to Rs 1,600 after Q2 results
HSBC has maintained a 'Hold' rating on Glenmark Pharma while trimming its target price to ₹1,600
Glenmark Pharmaceuticals Q2 FY25 Results: Revenue up 5.6% YoY to ₹3,433.80 crore, profit at ₹354.48 crore versus loss of ₹180.30 crore YoY
Glenmark Pharmaceuticals Ltd. reported a 5.6% year-on-year (YoY) increase in revenue from operations for Q2 FY25, reaching ₹3,433.80 crore compared to ₹3,207.38 crore in Q2 FY24. On a quarter-on-quart...
Glenmark Pharma Q2 results: Check share price ahead of Q2 results
Glenmark Pharmaceuticals shares are currently trading at ₹1,553.60, marking an increase of 0.92% as the company gears up to release its second-quarter earnings. With a total market cap of ₹43,840.75 c...
Stocks to Watch Today: Hindustan Aeronautics, Grasim, Hero MotoCorp, Muthoot Finance, Bharat Forge, Glenmark Pharma to announce Q2 results
Several companies are scheduled to announce their Q2 FY25 earnings today. The last traded price (LTP) from yesterday’s closing is provided below for each company, which could influence market reaction...
Glenmark Pharmaceuticals Q2 FY25 Results: Shares fall over 3% ahead of earnings release
Glenmark Pharmaceuticals Ltd shares were trading 3.25% lower at ₹1,525.75 on the NSE as of 11:37 a.m. on November 13, 2024, as investors anticipated the company’s Q2 FY25 results. Expectations for Gle...
Glenmark Pharma shares recover after 10% drop – Here’s what you need to know
Glenmark Pharmaceuticals shares experienced a sharp 10% plunge earlier today, trading at ₹1,634.7. However, the stock has started to show signs of recovery as of 9:29 AM, trading 1.18% lower at ₹1,614...
Glenmark Life Sciences shares jump 3% following ‘Buy’ upgrade by Kotak
Glenmark Life Sciences witnessed a surge of 3.15% in its share price, reaching ₹967.95 as of 11:38 AM on October 28, 2024. The stock saw positive momentum following Kotak’s double upgrade, which moved...
Pharma stocks update: IPCA Labs up 3.27%, JB Chem 3.18%, Glenmark 2.90%, Torrent Pharma 2.43%, Divis Labs 2.51%
The pharmaceutical sector showed strong momentum today, with multiple stocks posting notable gains by mid-afternoon. Investors showed increased confidence in pharma companies, driving up their stock p...
Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%
As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...
Here’s why Glenmark Pharma stock jumps 7.15% in early trade – Check out the reason behind the surge
At 9:30AM, Today, Glenmark Pharma shares surged by 7.15%, reaching ₹1,753.80 in early trade, after two positive developments. Firstly, Investec initiated a bullish valuation for the stock, noting it t...
Glenmark Pharma shares surge over 6% today as Investec initiates ‘FAST Long’, expects 17% upside
Glenmark Pharmaceuticals saw its shares jump over 6% on Monday morning after Investec initiated a “FAST Long” recommendation on the stock. The brokerage set a target price of ₹1,900, representing a po...
Investec initiates ‘FAST Long’ on Glenmark Pharma, expects stock to rally 17%
Investec has initiated coverage on Glenmark Pharmaceuticals with a "FAST long" recommendation, setting a target price of Rs 1900, which implies a 17.6% upside from the previous close of Rs 1615.
Glenmark Pharma receives zero observations from U.S. FDA at Aurangabad facility
Glenmark Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has completed an inspection of its formulation manufacturing facility in Chhatrapati Sambhaji Nagar (Aurangabad)...
Financial Crime Weekly: Drug Maker To Pay $25M For Price Fixing; Russians Busted For Propaganda; Nigerian Must Pay $5M For Phishing Scheme
Glenmark Pharmaceuticals Inc. USA , a generic pharmaceutical manufacturer in Mahwah, New Jersey, agreed to pay $25 million for allegedly conspiring to fix the price of a generic drug. The U.S. governm...
Glenmark Pharma settles US investigation with $25 million payment over five years
Glenmark Pharma Ltd. has reached a settlement with the US Department of Justice, agreeing to pay $25 million over five years to resolve an investigation into the company. This settlement is part of a ...
Glenmark Pharma shares hit record high after US Eye Allergy Drug launch
Glenmark Pharmaceuticals shares soared to a record high on Monday, following the launch of a new eye allergy drug in the US market by its subsidiary, Glenmark Therapeutics Inc.